Pure component contribution (PCCA) and synergy interval partial least squares (siPLS) algorithms for efficient resolution and quantification of overlapped signals; an application to novel antiviral tablets of daclatasvir, sofosbuvir and ribavirin
Open Access
- 31 December 2019
- journal article
- Published by European Journal of Chemistry in European Journal of Chemistry
- Vol. 10 (4), 350-357
- https://doi.org/10.5155/eurjchem.10.4.350-357.1899
Abstract
Daclatasvir (DAC), sofosbuvir (SOF) and ribavirin (RIB) have been recently co-formulated in tablet dosage form for the treatment of Hepatitis C virus infections. In this work, the resolution and quantitation of overlapped spectral signals was achieved by both univariate and multivariate algorithms. Pure component contribution algorithm (PCCA) as a novel approach was applied along with factor based partial least squares (PLS) algorithms using both full range and synergistic intervals (siPLS). Each drug could be determined at its λmax using PCCA, while PLS and siPLS were used for multivariate determination of the three components. Good linear relationships were obtained in the ranges of 5.45-16.35, 4.40-44.00 and 5.50-35.00 µg/mL for DAC, SOF and RIB, respectively, by PCCA. The PLS and siPLS models were built for the three compounds each in the concentration range of 2.00-10.00, 10.00-20.00 and 10.00-26.00 µg/mLfor DAC, SOF and RIB, respectively. Validation of the proposed methods was ascertained according to ICH guidelines for PCCA and through the use of internal and external validation sets for PLS and SiPLS models. The three methods were successfully applied for determination of DAC, SOF and RIB in pure form and in tablets.Keywords
This publication has 22 references indexed in Scilit:
- Stability-indicating micellar enhanced spectro-fluorometric determination of Daclatasvir in its tablet and spiked human plasmaSpectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, 2018
- Comparative study of six sequential spectrophotometric methods for quantification and separation of ribavirin, sofosbuvir and daclatasvir: An application on Laboratory prepared mixture, pharmaceutical preparations, spiked human urine, spiked human plasma, and dissolution testSpectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, 2018
- Daclatasvir-based Treatment Regimens for Hepatitis C Virus Infection: A Systematic Review and Meta-AnalysisHepatitis Monthly, 2016
- Daclatasvir–sofosbuvir combination therapy with or without ribavirin for hepatitis C virus infection: from the clinical trials to real lifeHepatic Medicine: Evidence and Research, 2016
- LP28 : Efficacy of the oral sofosbuvir-based combinations in HCV genotype 4-mono-infected patients from the french observational cohort anrs CO22 hepatherJournal of Hepatology, 2015
- Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV InfectionThe New England Journal of Medicine, 2014
- Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-lifeProceedings of the National Academy of Sciences of the United States of America, 2013
- Effect on Hepatitis C Virus Replication of Combinations of Direct-Acting Antivirals, Including NS5A Inhibitor DaclatasvirAntimicrobial Agents and Chemotherapy, 2012
- Epidemiology of hepatitis C virus infectionWorld Journal of Gastroenterology, 2007
- Multilevel Multifactor Designs for MultivariateCalibrationThe Analyst, 1997